
|Articles|May 1, 2004
PSA response after salvage therapy called useful endpoint
Boston--The fact that prostate cancer recurrence can be indolent may actually be detrimental to the development of drugs for patients in whom recurrence is life-threatening.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
2
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
3
Practical uses of AI across the urologic care continuum
4
New Data Influencing your Treatment Decisions in mCSPC
5



















